Loading…
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $85M | $-152M | $-140M | $-110M | -27.7% | 230194.6% | - |
| 2024 | $0M | $-181M | $-161M | $-138M | -31.5% | -99.8% | - |
| 2023 | $21M | $-107M | $-101M | $-79M | -32.8% | 562.3% | - |
| 2022 | $3M | $-106M | $-107M | $-98M | -46.5% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 3.13 | 20.72 | 0.04 | 85.21 |
| Operating Expense | 113.16 | 133.59 | 187.88 | 244.76 |
| Operating Income | -110.03 | -112.87 | -187.84 | -159.55 |
| EBITDA | -106.15 | -107.12 | -181.14 | -151.92 |
| EBIT | -110.03 | -112.87 | -187.84 | -159.55 |
| Pretax Income | -107.49 | -100.84 | -160.87 | -140.11 |
| Net Income | -107.49 | -100.84 | -160.87 | -140.11 |
| Net Income Common Stockholders | -107.49 | -100.84 | -160.87 | -140.11 |
| Total Expenses | 113.16 | 133.59 | 187.88 | 244.76 |
| Interest Income | 2.57 | 12.21 | 27.05 | 19.48 |
| Research And Development | 80.25 | 97.10 | 141.30 | 195.70 |
| Selling General And Administration | 32.91 | 36.49 | 46.58 | 49.06 |
| Normalized EBITDA | -106.15 | -107.12 | -181.14 | -151.92 |
| Normalized Income | -107.49 | -100.84 | -160.87 | -140.11 |
| Basic EPS | -3.32 | -2.58 | -2.98 | 0 |
| Diluted EPS | -3.32 | -2.58 | -2.98 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -107.49 | -100.84 | -160.87 | -140.11 |
| Reconciled Depreciation | 3.88 | 5.75 | 6.71 | 7.62 |
| Net Interest Income | 2.57 | 12.21 | 27.05 | 19.48 |
| Net Income From Continuing And Discontinued Operation | -107.49 | -100.84 | -160.87 | -140.11 |
| Total Operating Income As Reported | -110.03 | -112.87 | -187.84 | -159.55 |
| Diluted Average Shares | 32.35 | 39.13 | 53.94 | 0 |
| Basic Average Shares | 32.35 | 39.13 | 53.94 | 0 |
| Diluted NI Availto Com Stockholders | -107.49 | -100.84 | -160.87 | -140.11 |
| Net Income Including Noncontrolling Interests | -107.49 | -100.84 | -160.87 | -140.11 |
| Net Income Continuous Operations | -107.49 | -100.84 | -160.87 | -140.11 |
| Other Income Expense | -0.04 | -0.18 | -0.08 | -0.04 |
| Other Non Operating Income Expenses | -0.04 | -0.18 | -0.08 | -0.04 |
| Net Non Operating Interest Income Expense | 2.57 | 12.21 | 27.05 | 19.48 |
| Interest Income Non Operating | 2.57 | 12.21 | 27.05 | 19.48 |
| General And Administrative Expense | 32.91 | 36.49 | 46.58 | 49.06 |
| Other Gand A | 32.91 | 36.49 | 46.58 | 49.06 |
| Operating Revenue | 3.13 | 20.72 | 0.04 | 85.21 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| 4D Molecular Therapeutics, Inc.this co. | FDMT | $461M | - | 1.00 | -27.7% | -0.45 |
| agilon health, inc. | AGL | $465M | - | 3.65 | -308.8% | -0.53 |
| Ginkgo Bioworks Holdings, Inc. | DNA | $464M | - | 0.86 | -61.5% | -1.69 |
| Varex Imaging Corporation | VREX | $462M | - | 0.97 | -14.4% | 7.73 |
| Orthofix Medical Inc. | OFIX | $461M |
| - |
| 1.02 |
| -20.5% |
| -94.86 |
| MiMedx Group, Inc. | MDXG | $458M | 9.64 | 1.78 | 18.9% | 4.00 |
| Pacific Biosciences of California, Inc. | PACB | $456M | - | 81.67 | -10214.5% | -5.12 |
| Candel Therapeutics, Inc. | CADL | $453M | - | 6.53 | -73.5% | -8.07 |
| Larimar Therapeutics, Inc. | LRMR | $451M | - | 4.62 | -212.2% | -1.85 |
| Peer Median | - | 9.64 | 2.72 | -67.5% | -1.77 | |